Mirtazapine for Emesis Control

Introduction to Mirtazapine

• The National Comprehensive Cancer Network recommends antagonists 5-HT3, such as ondansetron, as the first line for non-chemotherapy-related emesis due to their superior efficacy and fewer side effects 1
• Alternative options for non-chemotherapy-related emesis include dopaminergic antagonists, corticosteroids, and benzodiazepines 2

Clinical Indications and Efficacy

• For patients with breast cancer who experienced delayed emesis after highly emetogenic chemotherapy, adding mirtazapine 15 mg daily on days 2-4 to the standard antiemetic regimen (aprepitant + 5-HT3 antagonist + dexamethasone 7.5 mg) resulted in a complete response rate of 78.3% with mirtazapine versus 49.0% without mirtazapine (p=0.003) 1
• Mirtazapine offers a statistically significant and clinically relevant benefit for delayed emesis control 2

Guideline Recommendations

• The American College of Clinical Pharmacy and other guideline societies support the use of mirtazapine as an adjunctive agent for emesis control, especially in cases where standard therapies fail 3
• Mirtazapine is not mentioned in the primary NCCN guidelines for non-chemotherapy-related emesis but may be considered based on its pharmacological profile 2

Safety and Precautions

• Common adverse effects of mirtazapine include somnolence and weight gain, which are generally mild to moderate 1
• Theoretical concern for bone marrow suppression requires monitoring before routine use in chemotherapy 2